Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Agosto 2024 - 3:15PM
Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology
company developing novel, investigational engineered cytokine
therapies designed to address areas of unmet need for patients with
a variety of cancers, today announced that on August 1, the Company
granted to one newly hired employee (i) non-statutory stock options
to purchase an aggregate of 13,000 ordinary shares of the Company
and (ii) restricted stock units with respect to an aggregate of
7,000 ordinary shares of the Company, pursuant to the Company’s
2024 Inducement Stock Option and Incentive Plan, each as an
inducement material to the new employees entering into employment
with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $3.48 per share,
which is equal to the closing price per share of the Company’s
ordinary shares as reported by Nasdaq on August 1, 2024. The
options have a ten-year term and vest over four years, with 25% of
the original number of shares vesting on the first anniversary of
the grant date and 6.25% of the shares underlying the options
vesting quarterly thereafter, subject to such employee’s continued
service with the Company through the applicable vesting dates. Each
of the stock options is subject to the terms and conditions of a
stock option award agreement covering the grant and the Company’s
2024 Inducement Stock Option and Incentive Plan. The restricted
stock units vest over four years, 25% per year on the anniversary
of the grant date, subject to such employee’s continued service
with the Company through the applicable vesting dates. Each of the
restricted stock units is subject to the terms and conditions of a
restricted stock award agreement covering the grant and the
Company’s 2024 Inducement Stock Option and Incentive Plan.
About Mural OncologyMural Oncology is
leveraging its novel protein engineering platform to develop
cytokine-based immunotherapies for the treatment of cancer. By
combining our expertise in cytokine biology and immune cell
modulation and our protein engineering platform, we are developing
medicines to deliver meaningful and clinical benefits to people
living with cancer. Our mission is to broaden the potential and
reach of cytokine-based immunotherapies to improve the lives of
patients. Our lead candidate, nemvaleukin, is currently in
potentially registrational trials in mucosal melanoma and
platinum-resistant ovarian cancer. Mural Oncology has its
registered office in Dublin, Ireland, and its primary facilities in
Waltham, Mass. For more information, visit Mural Oncology’s website
at www.muraloncology.com and follow us on LinkedIn and X.
Contact
Katie
Sullivankatie.sullivan@muraloncology.com
Mural Oncology (NASDAQ:MURA)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Mural Oncology (NASDAQ:MURA)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024